Norwich and Emerson team up and boost respective offerings

By Staff reporter

- Last updated on GMT

Related tags Pharmacology

US contract services firm Norwich Pharmaceuticals has teamed up with Emerson Resources in a partnership that both claim will help drug industry partners bring products to market.

The deal combines Norwich’s contract manufacturing and packaging operations with Emerson’s active pharmaceutical ingredient (API) characterisation, excipient and trial materials production services.

In the past few months Norwich has been adding to its roster of services. Just last month for example, the firm added pilot scale production and capacity to develop high potency compounds.

Prior to this, Norwich unveiled plans for a more comprehensive service offering to “assist customers throughout the life cycle of a product, as well as help… launch new initiatives, from line extensions to explorations into new product categories​.”

These moves were very much in keeping with efforts made by other contract services groups like Velesco, Patheon and ASG which have all recently announced plans to develop “one stop shop” business models.

“Clear path to commercialisation”

According to Norwich president Chris Calhoun, the new partnership with Emerson builds on the firms’ history of collaboration and will offer “a clear path to commercialisation for the clients of both our companies​.”

Calhourn denied that the move is designed to stave off the global economic downturn, and said that the partnership “ is an alliance of opportunity, not of necessity. When two strong companies come together under these circumstances, everybody wins​.”

Adolfo Gomez, Emerson’s president, echoed these thoughts, explaining that: ‘Both companies can bring faster, more flexible full-service capabilities to our customers, without the burdens of added bureaucracy that often hamper our competitors​.”

A joint management team will oversee projects undertaken by the two firms with individual management units taking charge of day to day research operations.

Emerson is expected to lead early-stage development, analytical and trial material manufacturing activities with Norwich taking responsibility for projects when they reach the Phase II clinical stage.

Norwich will also provide pharmaceutical industry clients with support for INDs, NDAs and ANDA and other regulatory application procedures.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more